257 related articles for article (PubMed ID: 38204331)
1. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.
Ringdén O; Sadeghi B
Stem Cells; 2024 Apr; 42(4):291-300. PubMed ID: 38204331
[TBL] [Abstract][Full Text] [Related]
2. Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
Ringden O; Baygan A; Remberger M; Gustafsson B; Winiarski J; Khoein B; Moll G; Klingspor L; Westgren M; Sadeghi B
Stem Cells Transl Med; 2018 Apr; 7(4):325-331. PubMed ID: 29533533
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
Ringdén O; Gustafsson B; Sadeghi B
Front Immunol; 2020; 11():567210. PubMed ID: 33193339
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease.
Sadeghi B; Remberger M; Gustafsson B; Winiarski J; Moretti G; Khoein B; Klingspor L; Westgren M; Mattsson J; Ringdén O
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1965-1969. PubMed ID: 31173898
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
Ringdén O; Moll G; Gustafsson B; Sadeghi B
Front Immunol; 2022; 13():839844. PubMed ID: 35371003
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
[TBL] [Abstract][Full Text] [Related]
8. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
Front Immunol; 2022; 13():959658. PubMed ID: 36189324
[TBL] [Abstract][Full Text] [Related]
9. Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation.
Aronsson-Kurttila W; Baygan A; Moretti G; Remberger M; Khoein B; Moll G; Sadeghi B; Ringdén O
Acta Haematol; 2018; 139(2):106-114. PubMed ID: 29408819
[TBL] [Abstract][Full Text] [Related]
10. Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua.
Moll G; Ignatowicz L; Catar R; Luecht C; Sadeghi B; Hamad O; Jungebluth P; Dragun D; Schmidtchen A; Ringdén O
Stem Cells Dev; 2015 Oct; 24(19):2269-79. PubMed ID: 26192403
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Front Immunol; 2022; 13():963445. PubMed ID: 36426365
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.
Yin F; Battiwalla M; Ito S; Feng X; Chinian F; Melenhorst JJ; Koklanaris E; Sabatino M; Stroncek D; Samsel L; Klotz J; Hensel NF; Robey PG; Barrett AJ
Stem Cells; 2014 May; 32(5):1278-88. PubMed ID: 24452962
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.
Kaipe H; Carlson LM; Erkers T; Nava S; Molldén P; Gustafsson B; Qian H; Li X; Hashimoto T; Sadeghi B; Alheim M; Ringdén O
Stem Cells Dev; 2015 Jun; 24(12):1471-82. PubMed ID: 25658253
[TBL] [Abstract][Full Text] [Related]
17. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease.
Ringdén O; Erkers T; Nava S; Uzunel M; Iwarsson E; Conrad R; Westgren M; Mattsson J; Kaipe H
Stem Cells; 2013 Mar; 31(3):592-601. PubMed ID: 23307526
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
Front Immunol; 2019; 10():619. PubMed ID: 31001253
[TBL] [Abstract][Full Text] [Related]
19. Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner.
Erkers T; Nava S; Yosef J; Ringdén O; Kaipe H
Stem Cells Dev; 2013 Oct; 22(19):2596-605. PubMed ID: 23701127
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
